Investor Overview Press Releases April 28, 2026 Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor April 27, 2026 Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 April 8, 2026 Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference View all » Events Apr 28, 20268:30 AM EDT Aclaris Clinical Program Update Apr 14, 202612:00 PM EDT H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference Mar 10, 20261:40 PM EDT Leerink Global Healthcare Conference View all » Feature Presentation March 2026 Corporate Overview
April 28, 2026 Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
April 27, 2026 Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
April 8, 2026 Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
